Fulgent Genetics Debt to Equity Ratio 2015-2025 | FLGT
Current and historical debt to equity ratio values for Fulgent Genetics (FLGT) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Fulgent Genetics debt/equity for the three months ending June 30, 2025 was 0.00.
| Fulgent Genetics Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-06-30 | $0.09B | $1.11B | 0.08 |
| 2025-03-31 | $0.08B | $1.12B | 0.07 |
| 2024-12-31 | $0.09B | $1.13B | 0.08 |
| 2024-09-30 | $0.10B | $1.14B | 0.09 |
| 2024-06-30 | $0.10B | $1.13B | 0.09 |
| 2024-03-31 | $0.10B | $1.13B | 0.09 |
| 2023-12-31 | $0.10B | $1.13B | 0.09 |
| 2023-09-30 | $0.10B | $1.26B | 0.08 |
| 2023-06-30 | $0.09B | $1.26B | 0.07 |
| 2023-03-31 | $0.11B | $1.27B | 0.09 |
| 2022-12-31 | $0.12B | $1.27B | 0.09 |
| 2022-09-30 | $0.12B | $1.28B | 0.10 |
| 2022-06-30 | $0.15B | $1.31B | 0.12 |
| 2022-03-31 | $0.15B | $1.31B | 0.12 |
| 2021-12-31 | $0.11B | $1.17B | 0.10 |
| 2021-09-30 | $0.16B | $1.04B | 0.15 |
| 2021-06-30 | $0.13B | $0.92B | 0.14 |
| 2021-03-31 | $0.20B | $0.80B | 0.25 |
| 2020-12-31 | $0.13B | $0.57B | 0.23 |
| 2020-09-30 | $0.06B | $0.19B | 0.32 |
| 2020-06-30 | $0.01B | $0.09B | 0.10 |
| 2020-03-31 | $0.01B | $0.08B | 0.10 |
| 2019-12-31 | $0.01B | $0.08B | 0.07 |
| 2019-09-30 | $0.01B | $0.06B | 0.12 |
| 2019-06-30 | $0.01B | $0.05B | 0.10 |
| 2019-03-31 | $0.01B | $0.05B | 0.11 |
| 2018-12-31 | $0.00B | $0.05B | 0.05 |
| 2018-09-30 | $0.00B | $0.05B | 0.04 |
| 2018-06-30 | $0.00B | $0.05B | 0.06 |
| 2018-03-31 | $0.00B | $0.05B | 0.05 |
| 2017-12-31 | $0.00B | $0.05B | 0.06 |
| 2017-09-30 | $0.00B | $0.06B | 0.06 |
| 2017-06-30 | $0.00B | $0.06B | 0.06 |
| 2017-03-31 | $0.00B | $0.06B | 0.06 |
| 2016-12-31 | $0.00B | $0.05B | 0.07 |
| 2016-09-30 | $0.01B | $0.02B | 0.32 |
| 2016-06-30 | $0.01B | $0.02B | 0.23 |
| 2016-03-31 | $0.00B | $0.00B | 0.00 |
| 2015-12-31 | $0.00B | 0.00 | |
| 2015-09-30 | $0.00B | $0.00B | 0.00 |
| 2015-06-30 | $0.00B | $0.00B | 0.00 |
| 2014-12-31 | $0.00B | $0.00B | 0.26 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.683B | $0.283B |
| Fulgent Genetics, Inc. provides genetic testing services to physicians with clinically actionable diagnostic information. The company's technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to hospitals and medical institutions. Fulgent Genetics is headquartered in Temple City, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $47.732B | 58.24 |
| Tempus AI (TEM) | United States | $12.524B | 0.00 |
| Doximity (DOCS) | United States | $11.721B | 48.51 |
| Hims & Hers Health (HIMS) | United States | $9.384B | 76.89 |
| IRhythm Technologies (IRTC) | United States | $5.716B | 0.00 |
| Hinge Health (HNGE) | United States | $3.454B | 0.00 |
| Privia Health (PRVA) | United States | $2.943B | 184.46 |
| Heartflow (HTFL) | United States | $2.876B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $2.435B | 40.29 |
| Enovis (ENOV) | United States | $1.624B | 8.53 |
| 10x Genomics (TXG) | United States | $1.618B | 0.00 |
| Omnicell (OMCL) | United States | $1.605B | 32.81 |
| Schrodinger (SDGR) | United States | $1.373B | 0.00 |
| Azenta (AZTA) | United States | $1.355B | 59.10 |
| Clover Health Investments (CLOV) | United States | $1.338B | 0.00 |
| Phreesia (PHR) | United States | $1.334B | 0.00 |
| Claritev (CTEV) | United States | $1.021B | 0.00 |
| Evolent Health (EVH) | United States | $0.705B | 0.00 |
| Talkspace (TALK) | United States | $0.568B | 113.00 |
| Butterfly Network (BFLY) | United States | $0.566B | 0.00 |
| Veradigm (MDRX) | United States | $0.545B | 0.00 |
| Standard BioTools (LAB) | United States | $0.431B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.402B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.320B | 0.00 |
| Carlsmed (CARL) | United States | $0.316B | 0.00 |
| TruBridge (TBRG) | United States | $0.289B | 13.27 |
| CapsoVision (CV) | United States | $0.225B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.220B | 0.00 |
| Outset Medical (OM) | United States | $0.210B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.208B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.186B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.183B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.171B | 0.00 |
| CareCloud (CCLD) | United States | $0.147B | 8.07 |
| EUDA Health Holdings (EUDA) | Singapore | $0.112B | 0.00 |
| NetraMark Holdings (AINMF) | Canada | $0.077B | 0.00 |
| Pulmonx (LUNG) | United States | $0.074B | 0.00 |
| American Well (AMWL) | United States | $0.066B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.058B | 0.00 |
| HeartBeam (BEAT) | United States | $0.056B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.040B | 0.00 |
| 111 (YI) | China | $0.037B | 0.00 |
| Precipio (PRPO) | United States | $0.033B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.027B | 0.00 |
| Lunai Bioworks (LNAI) | United States | $0.024B | 0.00 |
| Zhongchao (ZCMD) | China | $0.018B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.016B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.010B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.009B | 0.00 |
| PROFUSA (PFSA) | United States | $0.008B | 0.00 |
| HeartSciences (HSCS) | United States | $0.007B | 0.00 |
| Movano (MOVE) | United States | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.002B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.001B | 0.00 |